Slide 1: 1H FY26 Results Presentation
Epiminder Limited 1H FY26 Results Presentation 25th February 2026 Authorised for release by the Board of Directors © 2025 All rights reserved
Slide 2: Disclaimer
Disclaimer This disclaimer applies to this presentation and the information contained in it (the “Presentation”). By reading this disclaimer you agree to be bound by it. Important notice and disclaimer: This Presentation contains a general summary of the activities of Epiminder Ltd (Epiminder), does
Slide 3: Why Epiminder?
Why Epiminder? Significant unmet need and large addressable market, with approximately 1.1m adults with drug-resistant 01 epilepsy (DRE) in the US alone(1) . Epiminder’s groundbreaking Minder® medical device combines proprietary hardware and software, 02 developed in partnership with Cochlear, to pr
Slide 4: 1H FY26 & YTD Highlights
1H FY26 & YTD* Highlights Positive start to Next generation 2026 Medicare Historical R&D Prudent cost Sufficient cash DETECT device (G1) final ruling for claim resolved management reserves to reimbursement development on Minder® device favourably and complete DETECT program track completion. reimbur
Slide 5: Key objectives over next 24 months
Key objectives over next 24 months Activity Goal DETECT Generate cost-effectiveness and clinical value of the Minder® Enrollment complete H1 Demonstration system in US clinical practice for Payors (210 US patients to be CY2027 program implanted with Minder ®) Next generation Engineering complete H1
Slide 6: DETECT demonstration program
DETECT demonstration program Expected use of funds $25m over next 24 months Primary Demonstrate the cost-effectiveness and clinical value of the objective Minder® system in US clinical practice Primary Validate the proportion of actionable events captured by Minder® endpoint relative to the current
Slide 7: DETECT Enrolment progress
DETECT Enrolment progress Sites Forecast Enrolment Profile 210 Achieved Forecast 150 x3 100 50 25 1 3 Jan Feb May H1 CY2027 © 2025 All rights reserved
Slide 8: Clinician feedback
Clinician feedback I am thrilled to be able to offer this innovative technology as we implant our first patient in the DETECT study. Standard EEG methods do not offer the long-term EEG monitoring necessary to make informed management decisions for many of our patients. The ability to provide continu
Slide 9: State of the Art (G1) device development
State of the Art (G1) device development Expected use of funds $32m over next 24 months • Slim profile with a refined implantation technique • Native BLE communications G1 - a technologically • End-to-end cyber encryption advanced implant • Advanced manufacturing line at Manufacturing Partner • Hard
Slide 10: Near term revenue opportunities
Near term revenue opportunities Ahead of its full commercial launch in H1 CY2028, Minder® has a number of opportunities to develop "proof points" of penetrating the market • Epiminder is in discussions with multiple pharmaceutical companies regarding the use of Minder® in trials for new anti-seizure
Slide 11: 1H FY26 Summary Financials
1H FY26 Summary Financials
Slide 12: Profit & Loss
Profit & Loss $000's 1H FY26 1H FY25 Variance % • Adjacent table is how we will report going forward: Opex and Non Opex. Interest Income 429 226 90% 4,314 3,302 • 2H FY26 opex expected to broadly double Employment Expenses 31% DETECT Costs 474 630 -25% vs 1H FY26. 70% of cost increase driven by R&D
Slide 13: Balance Sheet
Balance Sheet $000's 1H FY26 June FY25 • Strong balance sheet post IPO Cash and Cash Equivalents 89,496 8,852 Prepayments, GST receivable 1,637 535 Current Assets 91,133 9,387 • Cash at 31 December 2025 was $89.5m Fixed Assets 70 71 Intangible Assets 13,150 13,150 Non Current Assets 13,220 13,221 As
Slide 14: Cash Flow
Cash Flow $000's 1H FY26 1H FY25 • Cash position and cash forecast has improved compared to prospectus driven Interest Receivable and Receipts 429 5,908 by ATO refund being $4.2m lower than DETECT Costs (308) (658) (4,886) (4,483) previous disclosure plus tailwind from FX G1 Costs Staff Costs (4,360
Slide 15: FY26 Outlook
FY26 Outlook Progression on DETECT and For 2H FY26, Epiminder expects a net Epiminder forecasts it has sufficient development of the G1 Minder device cash outflow of approximately $20m cash reserves to complete DETECT and is the priority. with the variability driven by the the next generation Minder
Slide 16: Appendix: Company Background
Appendix: Company Background
Slide 17: Epilepsy overview: The unmet need and economic burden
Epilepsy overview: The unmet need and economic burden ~52m ~3.4m ~1.1m People worldwide People in the US with epilepsy Adults in the US with with epilepsy drug resistant epilepsy ~US$28bn ~US$10.3bn ~US$1.1bn Direct annual healthcare Additional annual indirect healthcare Estimated annual target expe
Slide 18: Current technologies and techniques
Current technologies and techniques Current technologies and techniques have significant limitations – these shortcomings may result in diagnosis delays, misdiagnosis, ineffective and in some cases inappropriate treatment Patient diaries remain the only option for long-term monitoring, but Epilepsy
Slide 19: Minder is an integrated hardware and software system
Minder® is an integrated hardware and software system The Minder® System Minder® Implant Minder® Wearable Minder® App Minder® Cloud Comprises a sub-scalp electrode lead The Minder® Wearable receives and The Minder® App collects and transmits Minder® Cloud offers a secure online with multiple recordi
Slide 20: Minder provides actionable data over an extended monitoring window
Minder® provides actionable data over an extended monitoring window Minder® monitoring: Seizures captured over time(1) UMPIRE(1) clinical study Minder® delivered meaningful and actionable clinical insight for ~88% of patients c.88% Meaningful insight Examples of real observable outcomes ✓ Surgical r